Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01809093 · ClinicalTrials.gov registry record
Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.
A clinical trial, sponsored by Mid Atlantic Retina.
- Completed
- Registry status
- 90
- Enrollment target
NCT01809093: Completed study, sponsored by Mid Atlantic Retina.
NCT01809093 is a clinical trial that has completed, run by Mid Atlantic Retina. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01809093 has completed, sponsored by Mid Atlantic Retina.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.
Primary Outcome
Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.
Interventions
- BIOLOGICAL Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-03 |
What the finished NCT01809093 record still lists
NCT01809093 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT01809093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01809093 about?
NCT01809093 is a clinical study titled "Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.". You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.
What is the current status of trial NCT01809093?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2010-03. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01809093?
The interventions under investigation include: Blood draw (BIOLOGICAL).
Who is sponsoring clinical trial NCT01809093?
This trial is sponsored by Mid Atlantic Retina, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia